Actively Recruiting
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-07-22
350
Participants Needed
1
Research Sites
61 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.
CONDITIONS
Official Title
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated for hepatocellular carcinoma at Wuhan Union Hospital from July 2025 to July 2026
- Aged over 18 years old
- Have at least one CT or MR scan before treatment
- Confirmed diagnosis of hepatocellular carcinoma by tissue biopsy pathological examination
You will not qualify if you...
- Poor quality imaging data
- Incomplete clinical data or loss of follow-up
- Presence of another primary cancer besides liver cancer
- Unclear pathological diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
L
Lian Yang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here